Nektar Therapeutics
NKTR
144 hedge funds and large institutions have $1.48B invested in Nektar Therapeutics in 2014 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 42 increasing their positions, 56 reducing their positions, and 18 closing their positions.
293% more call options, than puts
Call options by funds: $17.1M | Put options by funds: $4.36M
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
39% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 18
5% more capital invested
Capital invested by funds: $1.4B → $1.48B (+$73M)
4% more funds holding
Funds holding: 138 → 144 (+6)
25% less repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 56
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Norges Bank
Oslo,
Norway
|
+$11.1M |
| 2 |
First Trust Advisors
Wheaton,
Illinois
|
+$9.39M |
| 3 |
State Street
Boston,
Massachusetts
|
+$5.75M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$3.46M |
| 5 |
Barclays
London,
United Kingdom
|
+$3.32M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$12.5M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$11.7M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$5.58M |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$4.51M |
| 5 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$4.37M |
NKTR Hedge Fund Activity: Q2 2014 in Review
144 of the 3,481 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q2 2014, worth a combined $1.48B — up 5.2% from $1.4B a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new NKTR positions and 18 closed out — a net gain of 7 holders — while 42 added to existing stakes and 56 trimmed.
The largest buyer was Norges Bank, adding an estimated $11.1M. The largest seller was T. Rowe Price Associates, cutting an estimated $12.5M.
- 144 institutional investors held Nektar Therapeutics (NKTR) as of Q2 2014, up from 138 in Q1 2014.
- Funds reported $1.48B of Nektar Therapeutics stock for Q2 2014, up 5.2% quarter-over-quarter.
- 25 funds opened new Nektar Therapeutics positions in Q2 2014 and 18 closed out, a net change of +7 holders.
- The largest Nektar Therapeutics buyer in Q2 2014 was Norges Bank, an estimated $11.1M added.
- The largest Nektar Therapeutics seller in Q2 2014 was T. Rowe Price Associates, an estimated $12.5M sold.
Based on aggregated 13F filings for Q2 2014.